When it comes to heart health, heart attacks tend to get the spotlight. While 805,000 people die from heart attacks every ...

Polygenic background bidirectionally modifies the penetrance of pathogenic variants in hypertrophic (HCM) and dilated (DCM) ...

Social determinants of health (SDOH) were found to be associated with increased risk of heart failure (HF) and ventricular arrhythmias (VA) in patients with hypertrophic cardiomyopathy (HCM), ...

These two conditions affect how well your heart can pump blood. Cardiomyopathy can sometimes lead to heart failure. Cardiomyopathy and heart failure are both conditions in which your heart has a more ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

The diagnosis of a potentially lethal cardiovascular disease in a young athlete presents a complex dilemma regarding athlete safety, patient autonomy, team or institutional risk tolerance and medical ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

Heart failure in which left ventricular ejection fraction recovers into the normal range has many unknowns. Andrew Perry, MD, discusses key management strategies with Jane Wilcox, MD, of Northwestern ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Heart failure is a progressive disease in which the myocardium weakens and cannot pump efficiently (systolic dysfunction) or fill adequately (diastolic dysfunction). Obesity has an important influence ...